What is the dose for an NAD+ injection?

There is no approved one. No FDA-approved injectable NAD+ drug product exists, so there is no label to quote and no regulator anywhere has set a dose. The only published human figure we can point at is from a randomised placebo-controlled pilot: 750 mg given as an intravenous infusion over six hours, at 2 mg per minute. The striking part of that study is the rate rather than the amount — six hours for 750 mg, with most participants still reporting nausea, headache, diarrhoea and muscle tightness during the infusion. Nothing in it establishes a subcutaneous dose, an efficacy dose, or a schedule, and we do not extrapolate one.

How much bacteriostatic water do I add to a 500 mg NAD+ vial?

Enough to make what you want to draw readable, which is a concentration decision and not a dose. 500 mg with 5 mL gives 100 mg/mL, so 50 mg would be 0.5 mL — 50 units on a U-100 syringe, half the barrel. With 2.5 mL you would be at 200 mg/mL and the same 50 mg would be 25 units. NAD+ vials are large compared with most peptides, so the practical limit is often the vial itself: most hold about 3 mL regardless of what the arithmetic suggests.

Is injectable NAD+ FDA-approved?

No. The FDA's 503A list places nicotinamide adenine dinucleotide in Category 1 — under evaluation, with no significant safety risk identified so far. Category 1 is neither approval nor inclusion on the bulks list; it means the evaluation has not concluded. Oral NAD+ precursors hold dietary supplement status, which is a different regulatory category again and says nothing about injecting it.

NAD+ Injection Dosage and Reconstitution Calculator

A dietary ingredient by mouth and an unapproved drug when injected. Small human infusion studies establish tolerability at a slow rate and nothing about efficacy.

Written by Kashif Khan, who builds and maintains this site and is not a clinician. Every figure links to its primary source.

Not approved

Category 1 under evaluation; no approved injectable product

The FDA's 503A list places nicotinamide adenine dinucleotide in Category 1 — under evaluation, with no identified significant safety risk. Category 1 is not approval and not inclusion on the bulks list. Oral NAD+ precursors hold dietary supplement status. There is no FDA-approved injectable NAD+ drug product; IV and subcutaneous NAD+ clinics operate on compounded, unapproved product.

No approved human dose exists for this compound in any country. The figures below are the doses used in named published studies, reproduced for reference only. Doses given to rats or mice do not convert to a human dose. The FDA has stated that labelling a product “research use only” or “not for human consumption” does not change its legal status when the seller's own marketing shows it is intended for people.

Calculator inputs

Set up your vial

Enter the label, dilution and dose. The result updates as you type.

Syringe volume

NAD+ in the vial

Vials sold online are commonly 100–1000 mg

Bacteriostatic water to add

Dose per injection

No approved human dose exists for this compound. The dose shown is only a calculator input, not a recommendation or starting point.

More optionsReverse calculation, schedule and cost

Enter the bacteriostatic water you added and get the volume to draw.

Injections per week

Discard afterdays

Vial priceoptional

Draw to

50units(0.5 mL)

Concentration: 100 mg/mL
Water added: 5 mL
Doses in vial: 10

How the concentration is calculated

This divides the peptide by the water you add. The powder occupies a little volume of its own, which is negligible on a typical vial but not on one with a heavy bulking agent. When a product label states a concentration, use the label’s number.

5 mL may exceed the capacity of a typical 3 mL vial. Check the vial before adding this much.

Key facts

Molecular weight: 663.4 Da
Half-life: Not published. No accessible human pharmacokinetic study reports one, so any specific figure quoted elsewhere has no primary source behind it.
Also sold as: nicotinamide adenine dinucleotide

Doses used in published studies

These are reproduced for reference. They are not recommendations, and an animal dose in mg/kg does not convert to a human dose.

humanintravenous infusion over 6 hours

750 mg at an infusion rate of 2 mg/min

Randomised placebo-controlled pilot in healthy adults. No vital-sign abnormalities or serious laboratory derangements versus placebo, but most participants reported nausea, headache, diarrhoea and muscle tightness during the infusion. The 6-hour duration is the point — it is the rate, not the dose, that is tolerated.

How good is the evidence?

Small pilot human infusion studies establish tolerability at a slow infusion rate and say nothing about efficacy. There is no evidence base for the anti-ageing claims it is sold under.

Oral and injected NAD+ are different regulatory objects

The same three letters describe two things with completely different legal standing. Oral NAD+ precursors hold dietary supplement status. Injectable NAD+ has no FDA-approved product at all, which makes any injected preparation an unapproved drug regardless of how the powder was sold to you.

The FDA's 503A list places nicotinamide adenine dinucleotide in Category 1 — under evaluation, with no identified significant safety risk to date. Category 1 is routinely presented by clinics as a form of endorsement. It is not approval, it is not inclusion on the bulks list, and it does not create an approved dose. It means the evaluation has not concluded.

What the human infusion data does and does not establish

The published human work is small and is about infusion rate rather than effect. What it establishes is tolerability at a slow rate — the cited study infused 750 mg over 6 hours, a rate of 2 mg per minute. That is the finding: at that rate it was tolerated.

It establishes nothing about efficacy for any of the purposes NAD+ is marketed for, and it is intravenous rather than subcutaneous, so it does not transfer to the route most vials are sold for. The slow rate is also the most practically relevant detail in the whole record, and it is the one most often dropped when the study is cited as support for a protocol.

Common questions

Sources

Every number on this page comes from one of the documents below. Where no reliable source exists, the page says so instead of filling the gap.

RegulatorFDA· 2026-05-14
Bulk Drug Substances Nominated for Use in Compounding Under Section 503A
RegulatorFDA
Bulk Drug Substances Used in Compounding Under Section 503A of the FD&C Act
Published studymedRxiv preprint· 2024
Intravenous NAD+ in healthy adults — a randomised placebo-controlled pilot
ReferenceNIH / National Center for Biotechnology Information
PubChem compound records (molecular weights and formulae)